muc1 peptide-poly-iclc vaccine
Colorectal Adenoma
National Cancer Institute (NCI)vaccinePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Colorectal Adenoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
UMBELLATINE Jing-yuan Fang, MD, Ph. D | Phase 2/3 | B |
Mesalamine UMC Utrecht | Phase 2 | B |
Dfn-15 University of Alabama at Birmingham | Phase 2 | B |
Linaclotide Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 | CCC |
Acetylsalicylic Acid University of Edinburgh | Phase 2 | CCC |
View all 11 →
Same molecule, other indications
muc1 peptide-poly-iclc vaccine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →